P481 - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATIC LIVER DISEASE (MASLD): EXPLORATORY ANALYSIS OF METABOLIC RISK FACTORS, LIVER CONDITION AND EFFECTS OF LIFESTYLE INTERVENTION.

P481

METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATIC LIVER DISEASE (MASLD): EXPLORATORY ANALYSIS OF METABOLIC RISK FACTORS, LIVER CONDITION AND EFFECTS OF LIFESTYLE INTERVENTION.

M. D. M. d'Orey^1,*, J. Estrabocha¹, S. Carvalhana^1,2, F. Capinha^1,2, S. Policarpo³, H. Cortez Pinto^1,4, O. Franco⁵, J. Massoels⁶, R. Grobbee⁷, M. Castro Cabezas⁷ on behalf of GRIP on MASH

¹Clinical Research Centre, Centro Académico de Medicina de Lisboa, Associação Para Investigação, Desenvolvimento Da Faculdade De Medicina, ²ULS Santa Maria, Gastroenterology Service, ULS Santa Maria, ³Dietetics and Nutrition, Nutrition Laboratory, Faculty of Medicine, University of Lisbon, ⁴Gastroenterology University Clinic, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, ⁵ Chair Healthy Living Chair Healthy Living , UMC Utrecht , Utrech, Netherlands, ⁶Chief Marketing Officer Chief Marketing Officer , Echosens, Paris, France, ⁷Universiteit Utrecht, Utrech, Netherlands

Rationale:  Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD), formerly Non-Alcoholic Fatty Liver, is diagnosed in the presence of hepatic steatosis and a cardiometabolic risk factor. Early diagnosis and lifestyle intervention (LI), including the Mediterranean Diet (MD) and Physical Activity (PA), is essential to prevent progression. The aim was to identify patients with risk factors for MASLD and, in the case of moderate fibrosis, to intervene in the LI.

Methods: Demographic, clinical (biochemical parameters, hepatic elastography -Fibroscan®- CAP for steatosis and LSM for stiffness) and nutritional (BMI, waist circumference-PC, dietary intake) data were collected. Individuals with moderate fibrosis received a 3-month intervention based on DM. The Healthy Eating Index (HEI) was calculated from the FFQ, an eating quality index (0-100); higher scores indicate a more cardioprotective pattern.

Results: 28 participants were included, 60.7% male, 96.4% overweight, of whom 74% were obese; 29.6 per cent had fibrosis and 37 per cent steatosis. After the intervention, 50 per cent of the participants reversed fibrosis, with a significant reduction in LSM (p=0.036), weight (p=0.04), PC (p=0.003) and neck (p=0.002). Weight loss ≥5% was associated with lower PAC values, with no impact on fibrosis. WC and neck circumference were associated with fibrosis (r=0.35;p=0.037 and p=0.44;p=0.012). Mean HEI between groups was 66.98 without fibrosis vs 68.85 with fibrosis, with no significant difference. SBP (r=0.55;p=0.002) and HOMA (r=0.51;p=0.004) suggest an influence of blood pressure and insulin resistance on fibrosis.

Conclusion: The prevalence of MASLD is on the rise. With only one approved drug, LI interventions that show potential to reverse fibrosis and reduce risk factors are essential.

Disclosure of Interest: M. D. M. d'Orey: None declared, J. Estrabocha: None declared, S. Carvalhana: None declared, F. Capinha: None declared, S. Policarpo: None declared, H. Cortez Pinto: None declared, O. Franco Grant / Research Support from: The GRIPonMASH project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101132946. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe, and Mercodia Aktiebolag, Metadeq Limited, and Julius Clinical Research BV. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them, J. Massoels Grant / Research Support from: The GRIPonMASH project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101132946. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe, and Mercodia Aktiebolag, Metadeq Limited, and Julius Clinical Research BV. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them, R. Grobbee Grant / Research Support from: The GRIPonMASH project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101132946. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe, and Mercodia Aktiebolag, Metadeq Limited, and Julius Clinical Research BV. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them, M. Castro Cabezas Grant / Research Support from: The GRIPonMASH project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101132946. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe, and Mercodia Aktiebolag, Metadeq Limited, and Julius Clinical Research BV. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them